Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and symptoms · community‐dwelling adults under 60 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in adverse events compared with lactulose (moderate certainty).
1 finding from 1 review